Conversely, pharmacological blockade of TLR4 activity tended to decrease the effect of NASH fEVs on IL‐6, IL‐8, CCL2 and CXCL1 production in endothelial cells. The gene discussed is TLR4; the disease is metabolic dysfunction-associated steatohepatitis.